Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$27.8 million.

  • Adma Biologics' Cash from Financing Activities fell 925.9% to -$27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.9 million, marking a year-over-year increase of 51.46%. This contributed to the annual value of -$58.3 million for FY2024, which is 4953.45% down from last year.
  • As of Q3 2025, Adma Biologics' Cash from Financing Activities stood at -$27.8 million, which was down 925.9% from $48000.0 recorded in Q2 2025.
  • Adma Biologics' Cash from Financing Activities' 5-year high stood at $62.7 million during Q4 2022, with a 5-year trough of -$39.0 million in Q4 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was -$319041.0 (2022), whereas its average is $5.1 million.
  • As far as peak fluctuations go, Adma Biologics' Cash from Financing Activities soared by 101433022.43% in 2021, and later tumbled by 622187.5% in 2024.
  • Over the past 5 years, Adma Biologics' Cash from Financing Activities (Quarter) stood at $53.8 million in 2021, then increased by 16.58% to $62.7 million in 2022, then crashed by 162.15% to -$39.0 million in 2023, then rose by 20.44% to -$31.0 million in 2024, then increased by 10.32% to -$27.8 million in 2025.
  • Its Cash from Financing Activities stands at -$27.8 million for Q3 2025, versus $48000.0 for Q2 2025 and -$7.1 million for Q1 2025.